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INTRODUCTION
It has been estimated that the number of new pros-
tate cancer（PCa）cases yearly is 164,690, and PCa is 
the second most common cause of cancer-related 
mortality for males in the United States. In Japan, 
78,400 new PCa cases are estimated yearly, and it is 
the sixth leading cause of cancer deaths 1,2）.
Currently, the primary diagnostic approaches for 
PCa are the serum prostate-specific antigen（PSA）
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SUMMARY
Aim：To assess the index lesions（the largest and clinically significant ones）in cases of surgically con-
firmed prostate cancer（PCa）using a multi-parametric MRI at 3 tesla and to evaluate the relationships 
between the clinical-pathological features of index PCas and cancer visualization.
Materials and Methods：This retrospective study included 67 patients who had undergone robotic-
assisted radical prostatectomy. Two radiologists reviewed the MRIs（axial and coronal T2-weighted imag-
ing, diffusion-weighted imaging（DWI）with apparent diffusion coefficient mapping and dynamic contrast 
enhancement MRI（DCEI））. The patients were divided into 4 groups as follows：detected on all 3 sequenc-
es（A）, on 2 of 3 sequences（B）, on 1 of 3 sequences（C）, and on none of them（D）. In all groups, all PCa 
characteristics were assessed, including the PSA level, Grade Group（GG）based on the Gleason score（GS）, 
the D’Amico criteria, and the maximum tumour length（TL）of the biopsy specimen.
Results：Of the 67 patients, 16 were high-risk according to the D’Amico criteria, and 15 of these 16 
high-risk patients（94％）belonged to either Group A or Group B. In addition, the mean TL and GG were 
longer and higher, respectively, in Group A than in the other groups（p＜0.05）. Furthermore, in Group B, 3 
of the 4 high-risk patients（75％）were detected using DWI and DCEI. The lesions detected using DWI 
and DCEI had higher GSs and were in a higher GG.
Conclusion：PCas of pathologically higher grades and clinically higher risk were more readily detectable 
using multiple parameters.
Key Words： Prostate cancer, multi-parametric MRI, dynamic contrast enhancement MRI, diffusion-
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test and/or an abnormal digital rectal examination
（DRE）. The standard PCa diagnostic pathway is biop-
sy guided by transrectal ultrasound（TRUS）and 
using multiple needles to systematically sample the 
entire prostate gland without knowledge of the likely 
locations of tumours.
Because of developments in magnetic resonance 
imaging（MRI）, including diffusion-weighted imaging
（DWI）, prostate MRI has become a common mode of 
detecting PCa. The PCa detection rate is particularly 
improved using the multi-parametric MRI（mp-MRI）
approach, which combines several imaging sequences, 
including T2-weighted imaging（T2WI）, DWI, 
dynamic contrast enhancement MRI（DCEI）, and, less 
commonly, MR spectroscopy. T2WI is the backbone 
of prostate imaging and provides both anatomical and 
structural information. DWI and DCEI are functional 
approaches, with the former reflecting the diffusibility 
of the water molecules in the intra- and extra-cellular 
spaces, and DCEI representing the vascularity in the 
PCa.
Although mp-MRI cannot depict all prostate lesions, 
in prostatectomy histologic correlation studies, mp-
MRI findings have shown that a tumour’s visibility 
and detectability depend on its size, volume3〜6） and 
Gleason score（GS）3,5,6）. Some studies have found that 
tumours larger than 1.0 cm or 0.5 cc and having a GS 
greater than or equal to 7 were detectable. However, 
these studies used a combination of approaches
（T2WI, DWI and DCEI）. In the Prostate Imaging 
Reporting and Data System（PI-RADS）version 2 7）, 
which is a relatively new way of using mp-MRI to 
detect PCas, the contribution of DCEI has been 
defined as secondary to those of T2WI and DWI 
because DCEI’s additional value has not been firmly 
established. Nevertheless, DCEI is often helpful in 
detecting PCas in actual clinical readings.
The purpose of the present study was to use mp-
MRI at 3T to assess index lesions, which are the larg-
est and most clinically significant ones, in cases of sur-
g i c a l l y c on f i rmed PCa and t o eva l u a t e t h e 
relationships between the clinical-pathological features 
of index lesions and cancer visualization.
MATERIALS AND METHODS
Patients
The Independent Ethics Committee of our hospital 
approved this retrospective study without the need 
for specific patient consent. The study included 151 
consecutive patients who had clinically significant can-
cer, which was defined as having a GS≥ 7 and/or a 
volume≥ 0.5 cc and/or an extra-prostatic extension, 
and who had undergone robotic-assisted radical pros-
tatectomy（RARP）between October 2012 and Decem-
ber 2014. The study’ exclusion criteria included prior 
hormonal or radiation treatment, lack of history of a 
prostate 3 tesla（3T）MRI in the year before the 
RARP and lack of a DCEI. The patients’ ages ranged 
from 55 to 76 years（median age 66 years）, with 
serum PSA values ranging from 3.7 to 30.7 ng/mL
（median 5.8 ng/mL）.
MR imaging Technique
The subjects were scanned using a 3T MR scanner
（Magnetom Trio Tim, Siemens Medical Solutions；
Erlangen, Germany）and a combination of a spine 
matrix coil（32 ch）and a body matrix coil（18 ch）. No 
endorectal coil was used. The patients had not been 
given laxatives and had not received an intramuscular 
injection of butyl scopolamine or glucagon before MR 
examination.
Axial T2WIs（repetition time（TR）/echo time（TE）
＝5000/93 ms）were obtained using a 3-mm thick-
ness, a 1-mm interslice gap, a 200×200 mm field of 
view（FOV）and a 320×320 matrix. The voxel size 
was 0 .625×0.625×3.0 mm, equalling a volume of 
1.17 mm3. The echo train length was 13.
DWIs were obtained, and an apparent diffusion coef-
ficient（ADC）mapping was calculated for each slice. 
Axial DWIs were obtained using a Stejskal-Tanner 
spin-echo echo-planar imaging sequence that had the 
following parameters：TR-TE of 6000/78 ms, flip 
angle of 90° , NEX of 6, b values of 0, 1000 and 1500 
s/mm2, matrix of 128×92, FOV of 350×250 mm, a 
slice thickness/gap of 3/1 mm to cover the entire 
prostate and a generalized autocalibrating partially 
parallel acquisition（GRAPPA）algorithm. The GRAP-
PA’s parameters were set to acceleration factors of 2. 
The voxel size was 2.734×2.734×3.0 mm, equalling a 
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volume of 22 .3 mm3 . The imaging location of the 
DWIs was identical to that of the T2WIs.
A gadolinium-DCEI during volumetric interpolated 
breath-hold examination was performed for a total 
acquisition time of 20 s in the axial orientation using a 
TR/TE of 3.5/1.3 ms, a matrix of 256×236, an FOV 
of 300×300 mm and a slice thickness/gap of 3/0 mm. 
The voxel size was 1 .17×1.27×3.0 mm, equalling 
4.47 mm3. For this dynamic scanning procedure, pre-
contrast baselines were sequentially obtained 50, 70 
and 90 s after bolus injection of 0.1 mmol/kg of gado-
pentetate dimeglumine（Magnevist, Bayer Schering 
Pharma；Berlin, Germany）, followed by a 15-mL 
saline flush-out at a rate of 3.0 mL/s. A 240-s delayed 
-phase series was added as a T1-weighted spin-echo 
image.
Image Interpretation
The MR images of the PCa patients were retrospec-
tively reviewed by two radiologists（one with 20 
years’ experience in reading prostate MRIs and the 
other with 5 years’ experience）who had no knowl-
edge of either the histopathologic findings or the clini-
cal data. When interpretations differed, the findings of 
the radiologist with 20 years’ experience were 
deferred to.
Although PI-RADS version 2 7） had already been 
released, PI-RADS version 1 8） was used to determine 
whether cancer was depicted on the MRI. This was 
because in PI-RADS version 2 , a DCEI can be 
assessed using only two scores（＋and−）, while in 
PI-RADS version 1, a DCEI can be assessed using an 
enhancement curve. Besides a scoret2wi 4-5 and a 
scoredwi 4-5 in PI-RADS version 1, we determined 
that both ’for focal enhancing lesion with curve type 
2-3（plateau or washout pattern）’ and ’asymmetric 
lesion or lesion at an unusual place with cure type 
2-3’ were a scoredcei 4-5. In each sequence, score 4-5 
was positive for cancer on the MRI（Table 1）. In 
cases of more than one cancerous region, the study 
targeted the largest lesion as determined using the 
histopathological findings from the prostatectomy.
Data and Statistical Analysis
The cases were divided into following four groups：
those detected on all three sequences（Group A；Fig-
ure 1）, on two of the three sequences（Group B；Fig-
ure 2）, on one of the three sequences（Group C）and 
Table 1　Cancer detection criteria
T2WI for PZ
4 Discrete, homogeneous low-signal focus/mass confined to the prostate
5 Discrete, homogeneous low-SI focus with extracapsular extension/invasive 
behavior of mass effect on the capsule（bulging）, or broad（＞1.5 cm）contact 
with the surface
T2WI for TZ
4 Areas of more homogeneous low SI, ill defined：“erased charcoal sign”
5 Same as category 4. but involving the anterior fibromuscular stroma or the 
anterior horn of the PZ. Usually lenticular or water-drop shaped
DWI
4 Focal areas of reduced ADC but isointense SI on high-b-value images
（b≥ 800 sec/min2）
5 Focal area/mass of hyper SI on high-b-value image（b≥ 800 sec/min2）with 
reduced ADC
DCEI
4 For focal enhancing lesion with curve type 2-3（plateau or washout pattern）
5 For asymmetric lesion of lesion at an unusual place with curve type 2-3
T2WI, T2-wighted imaging；DWI, diffusion-weighted imaging, DCEI, dynamic contrast 
enhancement magnetic resonance imaging；PZ, peripheral zone；TZ, transition zone；
SI, signal intensity；ADC, apparent diffusion coefficient.
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on none of them（Group D）. Based on previous stud-
ies 9〜12）, the fol lowing PCa characteristics were 
assessed：PSA level, Grade Group（GG）based on 
GS 13）, maximum tumour length（TL）of the biopsy 
specimen and D’Amico criteria 14）. D’Amico criteria are 
some of the most widely used for assessing PCa risk 
and are designed to evaluate the risk of recurrence 
following localized treatment of PCa. The GGs and 
GSs of both the biopsy specimen and the prostatecto-
my were evaluated. All parameters were statistically 
analysed using the Steel-Dwass test with R（version 
3.3.2）to enable multiple comparisons. A p£ 0.05 was 
regarded as statistically significant.
RESULTS
All 67 patients（mean age 66.0 years, median PSA 
5.91 ng/mL）met the study’s inclusion criteria. Table 2 
shows the PCa characteristics of each group in the 
study. 3T MRI with any sequence（T2WI, DWI or 
DCEI, respectively）could detect PCa with a higher 
sensitivity（83.6％；56/67）than could T2WI（55.2％；
37/67）, DWI（64.2％；43/67）and DCEI（64.2％；
43/67）（Table 2）.
Of the 67 patients, 29 were assigned to Group A, 13 
to Group B, 14 to Group C and 11 to Group D（Table 
3）. In addition, 16 of the 67 patients were high-risk 
according to the D’Amico criteria, and 15 of those 16
（94％）belonged to either Group A or B. The other 
high-risk patient belonged to Group D. There were 
statistically significant differences in the D’Amico cri-
ter ia between Groups A and C（p＝0 . 0 0 5）and 
between Groups A and D（p＝0.0072）. Furthermore, 
Figure 1
Multi-parametric MRI for a 75-year-old male with high risk prostate cancer（biopsy Gleason score 4＋4, 
robotic-assisted radical prostatectomy Gleason score 4＋5, prostate-specific antigen 5 .2 ng/mL）. （A）
T2-weighted imaging showed homogeneous hypo-intensity mass in the left peripheral zone（scoret2wi 4）. （B）
the mass had reduced apparent diffusion coefficient（scoredwi 5）. （C, D）dynamic contrast enhancement MR 
imaging showed asymmetric washout pattern（scoredcei 5）. This case was assigned to Group-A.
A B
C D
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Figure 2
Multi-parametric MRI for a 69-year-old male with high risk prostate cancer（biopsy Gleason score 4＋4, 
robotic-assisted radical prostatectomy Gleason score 4＋3, prostate-specific antigen 10.0 ng/mL）. （A）
T2-weighted imaging could not depict hypo-intensity mass clearly due to diffuse mild hypo-intensity in the 
peripheral zone（scoret2wi 3）. （B）the mass had reduced apparent diffusion coefficient（scoredwi 5）. （C, D）
dynamic contrast enhancement MR imaging showed asymmetric plateau pattern（scoredcei 5）. This case was 
assigned to Group-B.
BA
C D
Table 2　Patient characteristics classified by cancer-detected sequences
cancer-detected 
sequences（N）
median 
PSA
（ng/mL）
average 
TL
（mm）
D’Amico criteria
average 
GG 
Bx
average 
GS 
Bx
average 
GG 
RARP
average 
GS 
RARP
T2WI（37） 6.4 6.7 L6/Int 18/H13 2.6 7.1 2.9 7.3
DWI（43） 5.9 6.2 L6/Int 22/H 15 2.6 7.2 2.9 7.2
DCEI（43） 6.4 6.0 L5/Int 23/H15 2.7 7.2 2.9 7.3
any（56） 6.2 5.7 L10/Int 31/H 15 2.5 7.1 2.8 7.2
N, Number of patients；T2WI, T2-wighted imaging；DWI, diffusion-weighted imaging, DCEI, dynamic contrast 
enhancement magnetic resonance imaging；PSA, prostate-specific antigen；TL, maximum tumor length of the biopsy 
specimen；GG, Gleason grade group system based on Gleason scoring system；GS, Gleason scoring system, Bx, biopsy 
specimen；RARP, robotic-assisted radical prostatectomy；L, low risk；Int, intermediate risk；H, high risk.
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in the mean TL of the biopsy specimens, there were 
statistically significant differences between Groups A 
and C（p＝0.002）and between Groups B and C（p＝
0.028）. There were also statistically significant differ-
ences in the GGs of the biopsies between Groups A 
and C（p＝0.020）and Groups A and D（p＝0.034）. 
There were statistically significant differences in the 
average GSs of the biopsies between Groups A and C
（p＝0.043）and Groups A and D（p＝0.028）. In the 
GGs of the RARP cases, although the differences were 
not statistically significant, differences were observed 
between Groups A and B（p＝0.067）, Groups A and C
（p＝0.072）and Groups A and D（p＝0.064）.
3T MRI（used in groups A-C）had a 93.8％（15/16）
sensitivity in detecting index lesions in the high-risk 
patients. In Group B, the index lesions in 3 of the 4 
high-risk patients（75％）were detected using DWI 
and DCEI（Table 4）, and those lesions tended to have 
higher GSs（p＝0.073）and higher GGs（p＝0.086）, 
according to their biopsy results.
DISCUSSION
The results of the present study showed that the 
PCas detected on all three sequences were pathologi-
cally higher grade and clinically higher risk. In addi-
tion, the PCas detected on more than two sequences 
had a relationship with the TL of the biopsy speci-
men. Yoshida et al. 10） found that TL was strongly sig-
nificantly associated with PCas that could be detected 
using 3T MRI, and that result corresponds with those 
of the present study.
In the present study’s series, the sensitivities in 
detecting PCa were 83.6％（56/67）for mp-MRI, 56.7
％（38/67）for T2WI alone, 67.2％（45/67）for DWI 
alone and 65.7％（44/67）with DCEI alone. DWI was 
not shown to be superior to DCEI.
Although few studies have found a correlation 
between GS and DCEI, DCEI represents the micro-
vascular properties and angiogenesis using intrave-
nous gadolinium contrast. Lovegrove et al. 15） found 
that malignant prostate lesions had increased tumour 
vascularity and early and rapid enhancement, followed 
by a rapid washout of the contrast administered. DWI 
represents the random Brownian motion of water 
molecules. Because PCa causes increased cellularity 
and decreased extracellular spaces, it theoretically 
Table 3　Patient characteristics classified by group A-D（number of detected sequences）
group（N）
median
PSA
（ng/mL）
average
TL
（mm）
D’Amico criteria
average
GG
Bx
average
GS
Bx
average
GG
RARP
average
GS
RARP
A（29） 6.4 6.7 L1/Int 17/H 11 2.8 7.3 3.1 7.4
B（13） 6.4 6.2 L5/Int 4/H 4 2.4 7.0 2.4 7.0
C（14） 5.8 3.0 L4/Int 10/H 0 1.8 6.7 2.4 6.9
D（11） 5.6 3.8 L6/Int 4/H 1 1.7 6.4 2.4 7.2
N, Number of patients；PSA, prostate-specific antigen；TL, maximum tumor length of the biopsy specimen；GG, 
Gleason grade group system based on Gleason scoring system；GS, Gleason scoring system, Bx, biopsy specimen；
RARP, robotic-assisted radical prostatectomy；L, low risk；Int, intermediate risk；H, high risk.
Table 4　Patient characteristics classified in group B
subgroup（N）
positive 
sequences
median
PSA
（ng/mL）
average
TL
（mm）
D’Amico criteria
average
GG
Bx
average
GS
Bx
average
GG
RARP
average
GS
RARP
B1（4） DWI＋DCEI 6.2 6.5 L0/Int 1/H3 3.8 8.0 2.5 7
B2（6） T2＋DWI 7.7 5.3 L4/Int 1/H1 1.7 6.5 2 6.7
B2（3） T2＋DCEI 10.3 7.7 L1 / Int 2 / H0 2.0 6.7 3 7.7
N, Number of patients；PSA, prostate-specific antigen；TL, maximum tumor length of the biopsy specimen；GG, 
Gleason grade group system based on Gleason scoring system；GS, Gleason scoring system, Bx, biopsy specimen；
RARP, robotic-assisted radical prostatectomy；L, low risk；Int, intermediate risk；H, high risk.
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results in restricted diffusion. Some studies have noted 
that DWI may help to differentiate between low-risk 
and high-risk PCas 11,16,17）. Costa et al. 17） reported that 
clinically significant PCas had lower mean ADC values 
than those with clinically insignificant lesions（overall, 
0.598 vs. 0.803 mm/s2×10−3；PZ, 0.597 vs. 0.855 mm/
s 2×10−3；TZ, 0.600 vs. 0.660 mm/s 2×10−3）. Because 
a PCa that has a lower ADC value is more readily 
detectable using the ADC map, we evaluated the 
ADC map visually and saw a similar trend in the 
present study, although we did not measure ADC val-
ues.
In the present study, even in the group that was 
high-risk according to the D’Amico criteria, only 1 of 
67（1.4％）PCas could not be detected on any of the 
three sequences. In this case, the MR images were 
degraded by peristalsis and rectal gas. Although pros-
tate MRIs at 3T provide both a higher signal-to-noise 
ratio and high-quality images without the use of an 
endorectal coil, they are associated with a significant 
increase in imaging artefacts, including geometric dis-
tortion and signal graininess, especially DWIs 18）. 
Although the endorectal coil has some disadvantages, 
including patient discomfort, gland deformation and 
enema preparation, it is helpful not only for improving 
images but also for avoiding artefacts that result from 
rectal gas across the prostate.
Current mp-MRIs for PCa that are based on the 
PI-RADS version 2 7） scoring system have assessment 
categories for each lesion that are based on the scor-
ing of T2WI, DWI and DCEI sequences with the dom-
inant sequence, including T2WI for the transition 
zone and DWI for the peripheral zone. The present 
study found that the number of positive sequences in 
the three sequences（T2WI, DWI and DCEI）were 
related to the GS or the risk criteria. The approach to 
Category 3（equivalent to clinically significant PCa）
based on PI-RADS version 2 is still controversial 19,20）, 
and the results of the present study could suggest a 
simplified approach to evaluating and managing Cate-
gory 3 PCas.
The present study has some limitations, including 
its retrospective design, its single-centre site and 
some discrepancies in the GSs and GGs between the 
biopsy pathology and the RARP pathology. Discrepan-
cies in the GSs of specimens obtained using needle 
biopsies versus radical prostatectomies are common 
and universal 21）. In the treatment algorithms, the 
highest GS is typically used as the overall one, even if 
a lower GS predominates. This practice has the poten-
tial to misrepresent the overall cancer in the entire 
gland for some patients and places them in a higher 
GG22）.
In conclusion, PCas that were detectable on more 
than two sequences using prostate mp-MRI were 
pathologically higher grade and clinically higher risk.
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